Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz Pharmaceuticals' IPO: Taking Stock of VC Dilution

This article was originally published in Start Up

Executive Summary

The stockholder breakdown in Jazz Pharmaceuticals demonstrates how the company's founding VCs were significantly diluted by that company's massive Series B in 2004. As the company prepares for IPO it's worth considering how Ikaria Holdings' backers last month pulled in private equity support and managed to maintain their stakes in the company.

You may also be interested in...



Jazz Pharmaceuticals Improvises Its Way To A Turnaround

A day after specialty drug developer Jazz Pharmaceuticals Inc. announced plans to merge with Irish drugmaker Azur Pharma Ltd. in mid-September, the company had something new to celebrate. Jazz’s stock price reached an all-time high of $47.88 per share, giving the company a market valuation of almost exactly $2 billion.

Jazz Pharmaceuticals Improvises Its Way To A Turnaround

A day after specialty drug developer Jazz Pharmaceuticals Inc. announced plans to merge with Irish drugmaker Azur Pharma Ltd. in mid-September, the company had something new to celebrate. Jazz’s stock price reached an all-time high of $47.88 per share, giving the company a market valuation of almost exactly $2 billion.

Cash-Strapped Jazz Gets Stock Bump From Data On Fibromyalgia Candidate

Jazz Pharmaceuticals' stock price increased 39 percent on June 25, following the second announcement in a week of a successful Phase III trial for its fibromyalgia candidate, JZP-6 (sodium oxybate). The company's share price quickly retreated, dropping 56 cents on June 26 after analysts at Barclay's Capital downgraded the company because of concerns related to its financial health. Still the 21 percent increase in share value could position the specialty pharma to raise badly needed funds, given it has dwindling cash and defaulted on two recent quarterly interest payments on outstanding debt

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091389

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel